Shanghai Unicar-Therapy Bio-medicine Technology Co.Ltd
chimeric antigen receptor T cell(Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd)은 FRα 표적 세포·유전자 치료로, Pancreatic Cancer; CAR 영역에서 개발·상용화 중입니다. 작용기전: CAR-T cell therapy via IL-15-mediated cytokine competition in B-Cell lymphoma. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 67% (ClinicalTrials.gov NCT03704298). 차별점: novel bridging strategies to eliminate MRD and enable transplant are urgently needed.
FRα
Pancreatic Cancer; CAR
Active
CAR-T) therapy products for LBCL, yet a systematic comparison of
humanized antibody capable of recognizing both LILRB3 and LILRB4
novel bridging strategies to eliminate MRD and enable transplant are urgently needed
CAR-T cell therapy via IL-15-mediated cytokine competition in B-Cell lymphoma
cytokine release syndrome (CRS), all-grade and grade ≥ 3 immune effector cell-associated neurotoxicity syndro
HER2) expression, is a highly aggressive molecular subtype with high
resistance to dominant suppressive pathways such as TGF-β and adenosine signalling, improved trafficking and tissue penetration
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Shanghai Unicar-Therapy Bio-medicine Technology Co.Ltd
chimeric antigen receptor T cell(Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd)은 FRα 표적 세포·유전자 치료로, Pancreatic Cancer; CAR 영역에서 개발·상용화 중입니다. 작용기전: CAR-T cell therapy via IL-15-mediated cytokine competition in B-Cell lymphoma. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 67% (ClinicalTrials.gov NCT03704298). 차별점: novel bridging strategies to eliminate MRD and enable transplant are urgently needed.
FRα
Pancreatic Cancer; CAR
Active
CAR-T) therapy products for LBCL, yet a systematic comparison of
humanized antibody capable of recognizing both LILRB3 and LILRB4
novel bridging strategies to eliminate MRD and enable transplant are urgently needed
CAR-T cell therapy via IL-15-mediated cytokine competition in B-Cell lymphoma
cytokine release syndrome (CRS), all-grade and grade ≥ 3 immune effector cell-associated neurotoxicity syndro
HER2) expression, is a highly aggressive molecular subtype with high
resistance to dominant suppressive pathways such as TGF-β and adenosine signalling, improved trafficking and tissue penetration
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.